Ulipristal Acetate-d6

Modify Date: 2024-01-20 13:10:22

Ulipristal Acetate-d6 structure	Common Name	Ulipristal Acetate-d6
	CAS Number	1621894-64-1	Molecular Weight	481.66
	Density	1.2±0.1 g/cm3	Boiling Point	640.1±55.0 °C at 760 mmHg
	Molecular Formula	C₃₀H₃₁D₆NO₄	Melting Point	N/A
	MSDS	N/A	Flash Point	340.9±31.5 °C

Use of Ulipristal Acetate-d6

Ulipristal acetate-d6 is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma[1][2].

Name	Ulipristal Acetate-d6
Synonym	More Synonyms

Description	Ulipristal acetate-d6 is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma[1][2].
Related Catalog	Signaling Pathways >> Others >> Progesterone Receptor Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> Autophagy >> Autophagy
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Jadav SP, et al. Ulipristal acetate, a progesterone receptor modulator for emergency contraception. J Pharmacol Pharmacother. 2012 Apr;3(2):109-11. [3]. Del Bello B, et al. Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study. Fertil Steril. 2019 Dec;112(6):1150-1159. [4]. Hild SA, et al. CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod. 2000 Apr;15(4):822-9. [5]. Ciarmela P, et al. Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells. Reprod Sci. 2014 Sep;21(9):1120-5. [6]. Attardi BJ, et al. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. [7]. Pohl O, et al. Carcinogenicity and chronic rodent toxicity of the selective progesterone receptor modulator ulipristal acetate. Curr Drug Saf. 2013 Apr;8(2):77-97. [8]. Pohl O, et al. A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeys. Regul Toxicol Pharmacol. 2013 Jun;66(1):6-12.

Density	1.2±0.1 g/cm3
Boiling Point	640.1±55.0 °C at 760 mmHg
Molecular Formula	C₃₀H₃₁D₆NO₄
Molecular Weight	481.66
Flash Point	340.9±31.5 °C
Exact Mass	481.309906
LogP	4.48
Vapour Pressure	0.0±1.9 mmHg at 25°C
Index of Refraction	1.594

Estra-4,9-dien-3-one, 17-acetyl-17-(acetyloxy)-11-[4-(dimethyl-d3-amino)phenyl]-, (11β,17α)-

Ulipristal Acetate-d6

(11β)-11-(4-{Bis[(2H3)methyl]amino}phenyl)-3,20-dioxo-19-norpregna-4,9-dien-17-yl acetate

Ulipristal Acetate-d6

Use of Ulipristal Acetate-d6

Names

Ulipristal Acetate-d6 Biological Activity

Chemical & Physical Properties

Synonyms